Isabelle Rossi-Brenot

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients.

Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients.

Journal: EClinicalMedicine

Published: January 07, 2026

Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors.

Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors.

Journal: Frontiers in endocrinology

Published: January 29, 2025

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.

Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: August 29, 2024

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.

Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.

Journal: The Lancet. Oncology

Published: March 14, 2024

PET-MRI for evaluation of response to radiochemotherapy in patients with locally advanced cervical cancer.

PET-MRI for evaluation of response to radiochemotherapy in patients with locally advanced cervical cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 23, 2023

Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).

Radioisotope-guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients With Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).

Journal: The Journal of urology

Published: November 04, 2022

The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute's Experience.

The Management of a Comprehensive Cancer Center during the First Six Months of the COVID-19 Pandemic in the South of France: Lessons from the Paoli-Calmettes Institute's Experience.

Journal: Clinical hematology international

Published: June 16, 2021

Brachytherapy for oligometastatic prostate cancer to the penis.

Brachytherapy for oligometastatic prostate cancer to the penis.

Journal: Journal of contemporary brachytherapy

Published: May 27, 2021

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

Corrigendum to "French ccAFU guidelines-update 2020-2022: Prostate cancer" [Prog. Urol 30 (12 S) (2020), pp S136-S251].

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Published: May 04, 2021

French ccAFU guidelines - update 2020-2022: prostate cancer

French ccAFU guidelines - update 2020-2022: prostate cancer

Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie

Published: December 22, 2020

Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.

Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET.

Journal: Clinical genitourinary cancer

Published: December 16, 2020

EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas.

EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas.

Journal: Blood

Published: February 29, 2020

Showing 1-12 of 32

Last Updated: 09/26/2026